Atea Historical Cash Flow
| AVIR Stock | USD 3.73 0.06 1.63% |
Analysis of Atea PharmaceuticalsI cash flow over time is an excellent tool to project Atea PharmaceuticalsInc future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Stock Based Compensation of 26.4 M or Change In Working Capital of 17 M as it is a great indicator of Atea PharmaceuticalsI ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Atea PharmaceuticalsInc latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Atea PharmaceuticalsInc is a good buy for the upcoming year.
Atea |
About Atea Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Atea balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Atea's non-liquid assets can be easily converted into cash.
Atea PharmaceuticalsI Cash Flow Chart
Atea Cash Flow Statement became part of mandatory reporting in 1987. It is now one of three main statements in accounting used to measure how well a company manages its liquidity and overall cash position. The rate of cash utilization and preservation is now part of the leading indicators of a healthy entity, and the Atea PharmaceuticalsInc Cash Flow Statement shows how well the company generates cash to payout debt obligations or to cover ongoing operating expenses.
At this time, Atea PharmaceuticalsI's Investments are relatively stable compared to the past year. As of 04/23/2024, Change In Working Capital is likely to grow to about 17 M, while Stock Based Compensation is likely to drop slightly above 26.4 M. Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Most accounts from Atea PharmaceuticalsI's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Atea PharmaceuticalsInc current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atea PharmaceuticalsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. At this time, Atea PharmaceuticalsI's Investments are relatively stable compared to the past year. As of 04/23/2024, Change In Working Capital is likely to grow to about 17 M, while Stock Based Compensation is likely to drop slightly above 26.4 M.
| 2010 | 2023 | 2024 (projected) | Change To Inventory | 5.1M | 4.6M | 4.1M | Sale Purchase Of Stock | 531.7M | 1.3M | 1.3M |
Atea PharmaceuticalsI cash flow statement Correlations
Click cells to compare fundamentals
Atea PharmaceuticalsI Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Atea PharmaceuticalsI cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | (2K) | (26K) | (4K) | (455.4M) | 40.3M | 42.3M | |
| Change In Cash | (12.8M) | 828.5M | (85.5M) | (576.0M) | (44.6M) | (42.4M) | |
| Stock Based Compensation | 624K | 7.5M | 39.6M | 46.7M | 49.4M | 26.4M | |
| Free Cash Flow | (12.8M) | 296.7M | (87.0M) | (122.9M) | (85.4M) | (81.1M) | |
| Change In Working Capital | 579K | 300.2M | (247.8M) | (46.6M) | 16.2M | 17.0M | |
| Begin Period Cash Flow | 34.6M | 21.8M | 850.2M | 764.7M | 188.5M | 343.7M | |
| Total Cashflows From Investing Activities | (2K) | (26K) | (4K) | (455.4M) | (409.9M) | (389.4M) | |
| Other Cashflows From Financing Activities | (15K) | 214.1M | 1.5K | 140K | 40.3M | 37.6M | |
| Total Cash From Operating Activities | (12.8M) | 296.7M | (87.0M) | (121.0M) | (85.4M) | (81.1M) | |
| Change To Operating Activities | 407K | 5.1M | 43.2M | (44.6M) | (40.1M) | (38.1M) | |
| Issuance Of Capital Stock | 106.6M | 531.7M | 1.5M | 230K | 207K | 196.7K | |
| Net Income | (14.0M) | (10.9M) | 121.2M | (115.9M) | (136.0M) | (129.2M) | |
| Total Cash From Financing Activities | (15K) | 531.7M | 1.5M | 370K | 257K | 244.2K | |
| End Period Cash Flow | 21.8M | 850.2M | 764.7M | 188.7M | 143.8M | 136.6M | |
| Change To Netincome | 624K | 7.5M | 39.6M | 41.3M | 47.4M | 49.8M | |
| Change To Liabilities | 157K | 300.9M | (291.1M) | (2.0M) | (1.8M) | (1.7M) |
Pair Trading with Atea PharmaceuticalsI
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atea PharmaceuticalsI position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atea PharmaceuticalsI will appreciate offsetting losses from the drop in the long position's value.Moving together with Atea Stock
| 0.73 | EGRX | Eagle Pharmaceuticals | PairCorr |
Moving against Atea Stock
| 0.54 | DYAI | Dyadic International Financial Report 8th of May 2024 | PairCorr |
| 0.5 | VALN | Valneva SE ADR Financial Report 2nd of May 2024 | PairCorr |
| 0.47 | ELYM | Eliem Therapeutics | PairCorr |
The ability to find closely correlated positions to Atea PharmaceuticalsI could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Atea PharmaceuticalsI when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Atea PharmaceuticalsI - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Atea PharmaceuticalsInc to buy it.
The correlation of Atea PharmaceuticalsI is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Atea PharmaceuticalsI moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Atea PharmaceuticalsInc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Atea PharmaceuticalsI can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atea PharmaceuticalsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Complementary Tools for Atea Stock analysis
When running Atea PharmaceuticalsI's price analysis, check to measure Atea PharmaceuticalsI's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea PharmaceuticalsI is operating at the current time. Most of Atea PharmaceuticalsI's value examination focuses on studying past and present price action to predict the probability of Atea PharmaceuticalsI's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea PharmaceuticalsI's price. Additionally, you may evaluate how the addition of Atea PharmaceuticalsI to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
Is Atea PharmaceuticalsI's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atea PharmaceuticalsI. If investors know Atea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atea PharmaceuticalsI listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.641 | Earnings Share (1.63) | Revenue Per Share 2.31 | Quarterly Revenue Growth 2.952 | Return On Assets (0.12) |
The market value of Atea PharmaceuticalsInc is measured differently than its book value, which is the value of Atea that is recorded on the company's balance sheet. Investors also form their own opinion of Atea PharmaceuticalsI's value that differs from its market value or its book value, called intrinsic value, which is Atea PharmaceuticalsI's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atea PharmaceuticalsI's market value can be influenced by many factors that don't directly affect Atea PharmaceuticalsI's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atea PharmaceuticalsI's value and its price as these two are different measures arrived at by different means. Investors typically determine if Atea PharmaceuticalsI is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atea PharmaceuticalsI's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.